Harnessing host innate immunity may combat acquired resistance to BRAFi

Journal of Translational Medicine

Oral Presentation

Ennio Carbone¹  Pradeepa Pangigadde¹  Soldano Ferrone²  Elvira Favoino²  Francesco Sabbatino²  Thomas Tan³  Laura Orgiano³  Francesco Colucci³ 

[1] Karolinska Institute, Stockholm, Sweden;Università di Catanzaro Magna Graecia, Italy;Massachusetts General Hospital, Boston, United States;School of Clinical Medicine, University of Cambridge, United Kingdom;

关键词: Melanoma;    Natural Killer Cell;    Melanoma Cell;    Melanoma Patient;    Vemurafenib;   

DOI  :  10.1186/1479-5876-12-S1-O10

来源: Springer

【 授权许可】

Unknown   
© Tan et al; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.